Lantheus Holdings Research and Development Expenses 2013-2024 | LNTH

Lantheus Holdings research and development expenses for the twelve months ending September 30, 2024 were $0.150B, a 55.09% decline year-over-year.

  • Lantheus Holdings annual research and development expenses for 2023 were $0.078B, a 75.07% decline from 2022.
  • Lantheus Holdings annual research and development expenses for 2022 were $0.312B, a 593.15% increase from 2021.
  • Lantheus Holdings annual research and development expenses for 2021 were $0.045B, a 37.14% increase from 2020.

Lantheus Holdings Research and Development Expenses 2013-2024 | LNTH

  • Lantheus Holdings annual research and development expenses for 2023 were $0.078B, a 75.07% decline from 2022.
  • Lantheus Holdings annual research and development expenses for 2022 were $0.312B, a 593.15% increase from 2021.
  • Lantheus Holdings annual research and development expenses for 2021 were $0.045B, a 37.14% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$202.2B
Stryker (SYK)$143.3B
Boston Scientific (BSX)$130.1B
Medtronic (MDT)$112.5B
EssilorLuxottica (ESLOY)$111.7B
Lonza Group Ag (LZAGY)$45.4B
Haleon (HLN)$43.5B
GE HealthCare Technologies (GEHC)$39.3B
ResMed (RMD)$37B
Terumo (TRUMY)$29.6B
Koninklijke Philips (PHG)$25B
Zimmer Biomet Holdings (ZBH)$21.5B
Insulet (PODD)$18.8B
Baxter (BAX)$17.7B
Smith & Nephew SNATS (SNN)$10.6B
Bio-Rad Laboratories (BIO)$10.3B
BellRing Brands (BRBR)$9.1B
Demant (WILYY)$8.4B
Haemonetics (HAE)$4.5B
TG Therapeutics (TGTX)$4.5B
ICU Medical (ICUI)$4.3B
Prestige Consumer Healthcare (PBH)$4B
Perrigo (PRGO)$3.6B
Neogen (NEOG)$3.5B
Envista Holdings (NVST)$3.5B
Agios Pharmaceuticals (AGIO)$3.4B
GN Store Nord (GNNDY)$3B
Shandong Weigao Medical Polymer (SHWGF)$3B
QuidelOrtho (QDEL)$2.9B
LeMaitre Vascular (LMAT)$2.3B